Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Registry Study of Recombinant Human Natriuretic Peptide in Hospitalized Patients with Acute Heart Failure
ChiCTR2500112782Phase 4Not yet recruiting
- Sponsor
- Fuwai Hospital
- Start
- Nov 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nesiritide in Acute Heart Failure (AHF), sponsored by Fuwai Hospital. Primary endpoints: Rate of dyspnea improvement at 24 hours, Change from baseline in serum creatinine, eGFR, serum potassium, and Cystatin C and 3 more. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
nesiritide
03
Conditions
Acute Heart Failure (AHF)
Beyond the preview
Go deeper on ChiCTR2500112782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112782.